BAO PHARMA-B (02659) spent HKD 2.9931 million on September 4 to repurchase 183,400 shares.
Baoyi Pharmaceutical-B (02659) announced that on September 4, 2026, it repurchased 183,400 shares at a cost of HKD 2,993,100.
BAO PHARMA-B (02659) announced that on September 4, 2026, it spent HKD 2.9931 million to repurchase 183,400 shares.
Related Articles
The shareholder Weihai Bochuang and its concerted actions plan to reduce their holdings in Weihai Honglin Electronic (301439.SZ) by no more than 1%.
TCL ELECTRONICS (01070): Song Honghai has been appointed as the joint company secretary.
UNITED LAB (03933): The first dosage for the trial participant has been administered in the Phase III clinical study of UBT251 injection for obesity/overweight in China.
The shareholder Weihai Bochuang and its concerted actions plan to reduce their holdings in Weihai Honglin Electronic (301439.SZ) by no more than 1%.
TCL ELECTRONICS (01070): Song Honghai has been appointed as the joint company secretary.
UNITED LAB (03933): The first dosage for the trial participant has been administered in the Phase III clinical study of UBT251 injection for obesity/overweight in China.
RECOMMEND
